1. Field of the Invention. The present invention relates generally to medical systems and methods. More particularly, the invention relates to delivery systems having an ultrasound probe for improved imaging and a curved needle for ablation treatment, and methods for using the same.
Treatment of the female reproductive tract and other conditions of dysfunctional uterine bleeding and fibroids remain with unmet clinical needs. Fibroids are benign tumors of the uterine myometria (muscle) and are the most common tumor of the female pelvis. Fibroid tumors affect up to 30% of women of childbearing age and can cause significant symptoms such as discomfort, pelvic pain, mennorhagia, pressure, anemia, compression, infertility, and miscarriage. Fibroids may be located in the myometrium (intramural), adjacent the endometrium (submucosal), or in the outer layer of the uterus (subserosal). Most common fibroids are a smooth muscle overgrowth that arise intramurally and can grow to be several centimeters in diameter.
Current treatments for fibroids include either or both pharmacological therapies and surgical interventions. Pharmacological treatments include the administration of medications such as NSAIDS, estrogen-progesterone combinations, and GnRH analogues. All medications are relatively ineffective and are palliative rather than curative.
Surgical interventions include hysterectomy (surgical removal of the uterus) and myomectomy. Surgical myomectomy, in which fibroids are removed, is an open surgical procedure requiring laparotomy and general anesthesia. Often these surgical procedures are associated with the typical surgical risks and complications along with significant blood loss and can only remove a portion of the culprit tissue.
To overcome at least some of the problems associated with open surgical procedures, laparoscopic myomectomy was pioneered in the early 1990's. However, laparoscopic myomectomy remains technically challenging, requiring laparoscopic suturing, limiting its performance to only the most skilled of laparoscopic gynecologists. Other minimally invasive treatments for uterine fibroids include hysteroscopy, uterine artery ablation, endometrial ablation, and myolysis.
While effective, hysterectomy has many undesirable side effects such as loss of fertility, open surgery, sexual dysfunction, and long recovery time. There is also significant morbidity (sepsis, hemorrhage, peritonitis, bowel and bladder injury), mortality and cost associated with hysterectomy. Hysteroscopy is the process by which a thin fiber optic camera is used to image inside the uterus and an attachment may be used to destroy tissue. Hysteroscopic resection is a surgical technique that uses a variety of devices (loops, roller balls, bipolar electrodes) to ablate or resect uterine tissue. The procedure requires the filling of the uterus with fluid for better viewing, and thus has potential side effects of fluid overload. Hysteroscopic ablation is limited by its visualization technique and thus, only appropriate for fibroids which are submucosal and/or protrude into the uterine cavity.
Uterine artery embolization was introduced in the early 1990's and is performed through a groin incision by injecting small particles into the uterine artery to selectively block the blood supply to fibroids and refract its tissue. Complications include pelvic infection, premature menopause and severe pelvic pain. In addition, long term MRI data suggests that incomplete fibroid infarction may result in regrowth of infarcted fibroid tissue and symptomatic recurrence.
Endometrial ablation is a procedure primarily used for dysfunctional (or abnormal) uterine bleeding and may be used, at times, for management of fibroids. Endometrial ablation relies on various energy sources such as cryo, microwave and radiofrequency energy. Endometrial ablation destroys the endometrial tissue lining the uterus, and although an excellent choice for treatment of dysfunctional uterine bleeding, it does not specifically treat fibroids. This technique is also not suitable treatment of women desiring future childbearing.
Myolysis was first performed in the 1980's using lasers or radio frequency (RF) energy to coagulate tissue, denature proteins, and necrose myometrium using laparoscopic visualization. Laparoscopic myolysis can be an alternative to myomectomy, as the fibroids are coagulated and then undergo coagulative necrosis resulting in a dramatic decrease in size. As with all laparoscopic techniques, myolysis treatment is limited by the fact that it can only allow for visualization of subserosal fibroids.
Needle myolysis uses a laparoscope, percutaneous, or open technique to introduce one or more needles into a fibroid tumor under direct visual control. Radio frequency current, cryo energy, or microwave energy is then delivered between two adjacent needles (bipolar), or between a single needle and a distant dispersive electrode affixed to the thigh or back of the patient (unipolar). The aim of needle myolysis is to coagulate a significant volume of the tumor, thereby cause substantial shrinkage. The traditional technique utilizes making multiple passes through different areas of the tumor using the coagulating needle to destroy many cylindrical cores of the abnormal tissue. However, the desirability of multiple passes is diminished by the risk of adhesion formation which is thought to escalate with increasing amounts of injured uterine serosa, and by the operative time and skill required. Myolysis can be an alternative to myomectomy, as the fibroids are coagulated and then undergo coagulative necrosis resulting in a dramatic decrease in size. Myolysis is generally limited by its usage with direct visualization techniques, thus being limited to the treatment of subserosal fibroids.
To overcome the limitations of current techniques, it would be desirable to provide a minimally invasive approach to visualize and selectively eradicate fibroid tumors within the uterus. The present invention addresses these and other unmet needs.
The present invention is directed to delivery systems, and methods using the same, having an ultrasound probe for improved imaging and a needle for ablation treatment of target tissues. In some embodiments, the needle is straight with the ultrasound probe having an ultrasound array at a distal portion. In other embodiments, the needle is a curved needle. Typically, the needle will be deployed from within a natural or created body cavity or body lumen. Exemplary body cavities include the uterus, the esophagus, the stomach, the bladder, the colon, and the like. Exemplary body lumens include the ureter, the urethra, fallopian tubes, and the like. Created body cavities include insufflated regions in the abdomen, the thoracic cavity, regions around joints (for arthroscopic procedures), and the like. The present invention will generally not find use with procedures in blood vessels or other regions of the vasculature. Thus, while the following description will be directed particularly at procedures within the uterus for detecting and treating uterine fibroids, the scope of the present invention is not intended to be so limited. In an embodiment, the target tissue is a fibroid within a female's uterus.
In an embodiment, a rigid delivery system comprises a rigid delivery shaft, an imaging core, and an interventional core. In an embodiment, the rigid shaft having a proximal end, a distal end, and an axial passage extending through the rigid shaft. The axial passage will typically extend the entire length of the shaft from the proximal to the distal end, and is open at least at the proximal end. The shaft will usually be rigid along all or a portion of its length, but in other instances may be flexible, deflectable, or steerable.
In an embodiment, the imaging core preferably comprises an ultrasound imaging insert or probe disposed within the axial passage, usually being removably disposed so that it may be removed and replaced to permit sterilization and re-use. The imaging insert will have an ultrasound array within a distal portion thereof. In an embodiment, the ultrasound array is tilted relative to a shaft axis so as to provide an enhanced field of view, as discussed in more detail below. The ultrasound array may be tilted at an angle in a range from about 7 degrees to about 15 degrees, preferably in a range from about 7 degrees to about 10 degrees. It will be appreciated that the interventional core may be adapted for any conventional form of medical imaging, such as optical coherence tomographic imaging, direct optic visualization, and as such is not limited by ultrasonic imaging.
In an embodiment, the ultrasound imaging insert further comprises a flat viewing window disposed over the ultrasound array at the distal portion. The distal end of the rigid shaft may comprise a mechanical alignment feature, as for example, a flat viewing surface for axial or rotational orientation of the ultrasound imaging insert within the shaft. The flat viewing surface will be visually transparent to permit imaging from within the axial passage by the imaging insert. It will be appreciated, however, that the transparent visualization window which aids in physical alignment does not have to be visually transparent for ultrasound. For example, at least a portion of the flat viewing surface may be composed of an ultrasonically translucent material to permit ultrasonic imaging though the surface of the shaft. Further, the re-usable ultrasound imaging insert may be acoustically coupled to the outer delivery shaft to ensure that the ultrasound energy effectively passes from one component to the other. Ultrasonic acoustic coupling may be accomplished in several ways by one or a combination of means, including a compliant material (e.g., pad, sheet, etc.), fluid (e.g., water, oil, etc.), gel, or close mechanical contact between the rigid shaft and ultrasound imaging insert.
In an embodiment, the rigid delivery shaft preferably has a deflectable or fixed pre-shaped or pre-angled distal end. The delivery shaft distal end may be deflected or bent at an angle in a range from about 0 degrees to about 80 degrees relative to the shaft axis, preferably in a range from about 10 degrees to about 25 degrees. The ultrasound imaging insert will usually be flexible (and in some instances deflectable or steerable) so that the distal portion of the ultrasound imaging insert is conformable or bendable to the same angle as the shaft deflectable distal end. The cumulative effect of array tilting and shaft bending advantageously provides an enhanced viewing angle of the ultrasound imaging insert, which is in a range from about 7 degrees (i.e., angle due to tilted ultrasound array) to about 90 degrees relative to the shaft axis.
In a preferred embodiment, the viewing angle is about 20 degrees, wherein the array tilting and shaft bending are at about 10 degrees respectively. It will be appreciated that several geometries of array tilting and shaft bending may be configured so as to provide the desired viewing angle (e.g., distally forward direction, side-viewing or lateral direction), as for example, viewing of the end within the uterus (e.g., cornua and fundus).
In an embodiment, the interventional core preferably comprises a curved needle coupled to the rigid shaft via a needle guide. Significantly, an angle of needle curvature is dependent upon (e.g., inversely proportional to) the ultrasound array tilt and the shaft bend. For example, an increase in an angle of array tilting or shaft bending decreases an angle of needle curvature. This in turn provides several significant advantages such as allowing a treating physician or medical facility to selectively choose an appropriate needle curvature based upon such indications (e.g., variability in needle curvature). Further, a decrease in the angle of needle curvature provides for enhanced pushability, deployability, and/or penetrability characteristics as well as simplified manufacturing processes. The angle of needle curvature may be in a range from about 0 degrees to about 80 degrees relative to an axis, preferably the angle is about 70 degrees when the viewing angle is about 20 degrees. The curved needle generally comprises a two-piece construction comprising an elongate hollow body and a solid distal tip. The solid tip may comprise an asymmetric or offset trocar tip. For example, the tip may comprise a plurality of beveled edges offset at a variety of angles. It will be appreciated that the needle may take on a variety of geometries in accordance with the intended use.
In an embodiment, the needle extends adjacent an exterior surface of the rigid delivery shaft. In an embodiment, the needle is disposed within a needle guide which extends along an exterior of the rigid shaft. The curved needle may be removably and replaceably disposed within the guide passage. The guide passage will typically extend approximately the entire length of the shaft and be open at least at the distal end so as to allow the needle to be reciprocatably deployed and penetrated into adjacent solid tissue. In an embodiment, the needle has a hollow body and a solid distal tip formed from conductive material. The needle, optionally, may be covered, at least along a distal portion of the needle body, with a sheath. In an embodiment, the sheath is retractable such that the needle distal tip is extendable from a sheath's distal end thereby adjusting the length of the exposed conductive distal tip. In an embodiment, the sheath is formed from non-conductive material such as parylene.
In an embodiment, the curved needle and needle guide have a flattened oval shape that has a wideness that is greater than a thickness. This oval cross sectional shape is intended to inhibit lateral deflection during deployment or penetration of the needle. The needle is configured to deliver to the target site radio frequency energy (or other ablative energy such as, but not limited to, electromagnetic energy including microwave, resistive heating, cryogenic) generated at a relatively low power and for relatively a short duration of active treatment time.
In an embodiment, a delivery system includes a shaft, an imaging core, and an interventional core. The delivery shaft has a proximal end, an angled distal tip, and an axial passage therethrough. The imaging core comprises an ultrasound imaging insert disposed within the axial passage. The imaging insert has an ultrasound array within a distal portion thereof, wherein the ultrasound array is tilted relative to a shaft axis. The interventional core comprises a curved ablation needle coupled to the shaft. An angle of needle curvature may be inversely proportional to the ultrasound array tilt and tip angle.
As discussed above, the geometries of the shaft, imaging insert, treatment needle, and needle guide may be varied in accordance with the intended use. The delivery shaft, ultrasound imaging insert, treatment needle, and/or needle guide may be integrally formed or fixed with respect to one another or preferably comprise separate, interchangeable modular components that are coupleable to one another to permit selective sterilization or re-use, and to permit the system to be configured individually for patients having different anatomies and needs. For example, a sterilizable and re-usable ultrasound insert may be removably positioned within a disposable shaft.
The target site undergoing treatment may be any target site which may benefit from the treatment devices and methods according to the present invention. Usually the target site is a uterus within a female's body. The target site in need of treatment generally has an initial (e.g., prior to treatment) approximate diameter which is greater than about two (2) centimeters (“cm”). Usually, the target site's initial diameter ranges from about 1 to about 6 cm. Normally the initial untreated diameter is about 2 cm.
In an embodiment of methods according to the present invention for visualization and ablation of fibroid tissues needing treatment within a patient's body include providing a visualization and ablation system according the device and system embodiments described herein. In an embodiment, the method comprises inserting a rigid shaft having a proximal end, a distal end, and an axial passage therethrough within a uterus. The distal end of the rigid shaft may then be selectively deflected. An ultrasound imaging insert may then be loaded within the axial passage prior to, concurrent with, or subsequent to shaft insertion, wherein a distal portion of the insert conforms to the deflected shaft distal end. Loading may further involve axially or rotationally aligning the ultrasound imaging insert within the rigid shaft. A needle curvature is then selected by the physician or medical facility from a plurality of needles (i.e., at least two or more) having different curvatures based on at least an angle of the deflected shaft distal end. The selected curved needle is then loaded along the rigid shaft. Under the guidance of the imaging system, the needle is inserted into the tissue site. The RF generator is set to deliver and/or maintain a target temperature at the target site for a treatment period.
In an embodiment, the ultrasound array may be tilted or inclined within the distal portion of the insert, wherein selecting the needle curvature further comprises accounting for the ultrasound array tilt. As described above, the ultrasound array is preferably tilted at an angle in a range from about 7 degrees to about 10 degrees relative to a shaft axis. Deflecting will typically comprise pulling a pull or tensioning wire coupled to the shaft distal end in a proximal direction. Deflection occurs at an angle in a range from about 0 degrees to about 80 degrees relative to the shaft axis, wherein the needle curvature is in a range from about 0 degrees to about 90 degrees (i.e., in the case of a non-tilted ultrasound array) relative to an axis. The method further comprises imaging the uterus with a viewing angle of the ultrasound array in a range from about 0 degrees to about 90 degrees (i.e., in the case of a straight needle) relative to the shaft axis, wherein the viewing angle is based upon the deflected shaft distal end and the tilted ultrasound array. It will be appreciated that torquing and/or rotating the rigid device in addition to tip deflection and ultrasound tilt will allow a physician to obtain the desired viewing plane.
In some embodiments, methods further include ablating a uterine fibroid within the uterus with the selected curved needle. In those cases, the needle may be a radiofrequency (RF) electrode, a microwave antenna, a cryogenic probe, or other energy delivery or mediating element intended for ablating or otherwise treating tissue. The distal tip of the needle will usually be adapted so that it will self-penetrate into the tissue as it is advanced from the needle guide. The direction of advancement will be coordinated with the imaging field of the ultrasound insert so that the penetration of the curved needle can be viewed by the physician, usually in real time. Further, an electrolyte (e.g., saline) or other agent may be infused within the uterus prior to or concurrently with fibroid ablation so as to enhance the therapeutic effect provided by the treatment needle. This is preferably accomplished by providing at least one or more (e.g., two, three, four, five, etc.) infusion holes or apertures on the needle body. In still other cases, the needle could be a hollow core needle intended for sampling, biopsy, otherwise performing a diagnostic procedure.
In an embodiment, the power and temperature are generated by a radio frequency energy generator. The radio frequency energy generator is generally configured to deliver energy at a power from about 1 to about 50 watts (“W”), generally from about 1 to about 40 W, usually from about 20 to about 40 W, and normally about 30 W. The radio frequency energy generator is further configured to provide a target temperature at the target site ranging from about 50 to about 110 degrees Celsius (“.degree. C.”), usually from about 60 to about 100.degree. C., normally about 90.degree. C. In an embodiment, the needle's conductive tip is at approximately body temperature as it is initially disposed within the patient's body.
In an embodiment, the target site is treated for a period of time ranging from about 1 to about 10 minutes, generally from about 1 to about 8 minutes, usually from about 3 to about 8 minutes, normally about 6 minutes.
In an embodiment, at least one fluid lumen extends along the rigid shaft for delivering fluids to a distal portion of the delivery system. The at least one fluid lumen may be configured for delivery of any one or more of fluids such as those for enhancing acoustic coupling between the ultrasound imaging insert and the target site, contrasting dyes, therapeutic agents, and the like. In an embodiment, the at least one fluid lumen includes acoustic coupling lumens including an internal lumen extending along the axial passage and terminating at an internal port within its distal end and an external lumen extending along the axial passage and terminating at an external port in fluid communication with the outside of the axial lumen. In an embodiment, the external lumen is formed by an external hollow tubular body extending along the needle guide, while the internal lumen is formed by an internal hollow tubular body extending along the underside of the axial hollow tubular body forming the axial passage. It should be appreciated, however, that the external and internal fluid lumens may be oriented in any other suitable location along the shaft. In the embodiment, as shown, the external lumen is located along the needle guide such that the fluid may exit near the ultrasound window, while the internal lumen extends along the underside of the axial hollow tubular body which forms the axial passage so as to allow the fluid to be delivered to the inner tip without trapping air inside the shaft.
In an embodiment, the present invention includes a visualization and ablation system generally having a delivery device, an ultrasound imaging probe detachable from the delivery system, a radio frequency energy generator, and an ultrasound system.
The following drawings should be read with reference to the detailed description. Like numbers in different drawings refer to like elements. The drawings illustratively depict embodiments including features of the present invention. The drawings are not necessarily drawing to scale and are not intended to limit the scope of the invention.
Referring to
The curved needle 14 has a needle body 50 with a shaped needle distal end 52 and a solid needle distal tip 54, as best seen in
Now referring back to
The shaft axial passage 32 is configured for removably and replaceably receiving and housing an ultrasound imaging insert 70. A sealing element 72 may be provided between the ultrasound imaging insert 70 and the shaft handle 40 to provide sufficient sealing around the imaging insert 70 at a proximal end.
The ultrasound imaging insert 70 as shown in
Referring now to
Referring now to
In an embodiment, the deflectable distal tip 28 of the rigid shaft 24 may be deflected by the use of pull or tensioning wire(s) housed within the shaft 24. Deflection may occur at a true mechanical pivot or at a flexible zone at the shaft distal end 26. When the delivery shaft 24 is deflectable by a user, various needles 14 may be used to match the amount of deflection provided by the distal tip 28 as well as the amount of tilt provided by the ultrasound array 80. Hence, the needle guide 58 will typically be empty until the distal end 26 of the shaft 24 is deflected. For example, the shaft 24 may be inserted in a straight configuration. The distal tip 28 may then be deflected until a target anatomy is identified. A needle 14 is then back loaded within the guide passage 58 that corresponds to the amount of the deflection.
The delivery system 10, as shown in various
The shaft 24 of the present invention, as described herein, may serve several functions including delivering ultrasound, diagnostic, and/or interventional treatments, bending of the ultrasound insert via the deflectable distal tip, and/or providing a sterile barrier between the ultrasound and/or interventional components. As shown in
Generally, the delivery system shaft 24 will have a length in a range from about 20 cm to about 40 cm and an outer diameter in a range from about 3 mm to about 10 mm, while the ultrasound imaging insert 70 will have a length in a range from about 50 cm to about 90 cm and an outer diameter in a range from about 2 mm to about 4 mm. Delivery system shaft 24 and the ultrasound imaging insert 70 may be acoustically coupled in one or more of several ways to enable the effective passage of ultrasound energy from one component to the other. For example, the ultrasound insert 70 may be placed in close mechanical contact with the shaft 24 so as to provide a dry coupling. In addition or alternatively, a thin compliant layer (e.g., pad or sheet) may be disposed between the viewing windows 82 and 12, of the ultrasound insert 70 and the shaft 24, respectively, so as to provide further interference between such components. It will be appreciated that a thinner layer may be preferred to minimize unwanted acoustic loss, index of refraction, impedance, and/or other material property effects. Alternatively, or in addition to, the shaft axial passage 32 in which the ultrasound imaging insert 70 is disposable, may be filled with a fluid (e.g., water or oil) or gel to further provide a wet coupling between the shaft and the imaging insert which may compensate for any mechanical tolerances.
Now referring to
The ultrasound probe 300 embodying features of the present invention, as shown in
The ultrasound system 500, embodying features of the present invention, as shown in
The radio frequency energy 410, embodying features of the present invention, and as shown in
Now referring to
As best seen in
Referring now to
The needle body 50 is formed from an RF energy conductive material such as stainless steel. As will be appreciated, the solid tip 54 may comprise a variety of dimensions and shapes and is not limited to
In an embodiment, as shown in
The insulating sheath 140 may be formed from one or more suitable insulating material such as polyester shrink tubing, and parylene coating such as parylene C. Generally, the length of the conductive distal tip 54 ranges from about 1 to about 4 cm, usually from about 2 to about 3 cm, normally about 2 cm. In an embodiment, the conductive distal end is a T-type active electrode.
Now referring back to
The target site 16, such as fibroid 18, generally has an initial untreated diameter greater than about 2 cm, usually from about 1 to about 6 cm, normally about 2 cm. During the treatment of the fibroid 18, the needle 14 may be inserted one or more times into the tissue as may be necessary. In an embodiment, the needle distal tip 54, may be deployed into the tissue, up to 3 cm as measured from the distal end of the of the delivery device 10. During the treatment, the deployed length of the needle penetrating the tissue is visualized through the ultrasound imaging system 500.
By way of operation, in an embodiment, the deflectable distal tip 26 of the rigid shaft 24 may be deflected by the use of pull or tensioning wire(s) housed within the shaft 24. In another embodiment, the distal tip may have pre-determined deflection as compared to a longitudinal axis at a proximal portion of the device. Deflection may occur at a true mechanical pivot or at a flexible zone at the shaft distal end. When the delivery shaft 24 is deflectable by a user, various needles 14 may be used to match the amount of deflection provided by the distal tip 26 as well as the amount of tilt provided by the ultrasound array 80. Hence, the needle guide 58 may be empty until the distal end 26 of the shaft 24 is deflected. For example, the shaft 24 may be inserted in a straight configuration. The distal tip 26 may then be deflected until a target anatomy is identified. A needle 14 is then back loaded within the guide passage 70 that corresponds to the amount of the deflection. Alternatively, the needle may be pre-loaded in the shaft to provide a sterile and convenient delivery device to the user.
In exemplary embodiments, the therapeutic needle 14 advancement from the guide 58 via needle advancement portion on the shaft handle 40 can be viewed in the ultrasound system 500 in real time as it is penetrated into the uterine fibroid 18 inside the uterus 17. The therapeutic needle 14 may be penetrated in several configurations (e.g., lateral, side, axially extending) depending on the ultrasound viewing angle. Advantageously, tilting of the ultrasound array 80 and angling of the distal tip 26 allows a treating physician to image most or all of the cornua and fundus of the uterus 17 with a single device 10.
Now referring back to the previous Figures, Table I below illustrates possible viewing angles κ that may be achieved by the cumulative effects of the shaft bending angle β (e.g., either through active deflection of the distal tip or a pre-shaped or pre-bent distal tip) and the ultrasound tilting angle α. The matching needle angles θ based on the possible viewing angles κ are further illustrated. In example 1, the shaft 24 is in a straight configuration so that the viewing angle κ is provided solely by the tilting angle α of the ultrasound array 80. In example 4, the needle 14 will have a straight configuration. In example 5, a non-tilted and non-bent ultrasound array 80 version is covered. It will be appreciated that the viewing angle κ will be more than the bend angle β of the shaft 24 due to the additive effect of the tilting angle α of the ultrasound array 80. This allows the bend on the distal tip 28 of the shaft 24 to be shallower without compromising the cumulative viewing angle κ, which is of particular benefit for patient insertion considerations. In the case of a deflectable distal tip 28 in which insertion may be implemented in a straight configuration, the tiled ultrasound angle α still aids in reducing the needle angle θ.
Referring now to
In exemplary embodiments, the therapeutic needle 14 advancement from the guide 58 via needle advancement button on the shaft handle 40 can be viewed in real time as it is penetrated into the uterine fibroid 18 inside the uterus 19 as illustrated by the viewing plane 11 in
Referring now to
Although certain exemplary embodiments and methods have been described in some detail, for clarity of understanding and by way of example, it will be apparent from the foregoing disclosure to those skilled in the art, that variations, modifications, changes, and adaptations of such embodiments and methods may be made without departing from the true spirit and scope of the invention. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
This application is a continuation of U.S. application Ser. No. 13/667,891, filed Nov. 2, 2012, now U.S. Pat. No. 10,058,342; which is a continuation-in-part of U.S. application Ser. No. 12/973,587, filed Dec. 20, 2010, now U.S. Pat. No. 8,506,485; which is a continuation of U.S. application Ser. No. 11/564,164, filed Nov. 28, 2006, now U.S. Pat. No. 7,874,986; which is a continuation-in-part of U.S. application Ser. No. 11/409,496, filed Apr. 20, 2006, now U.S. Pat. No. 7,815,571; the full disclosures of which are incorporated herein by reference; U.S. application Ser. No. 13/667,891 is also a continuation-in-part of U.S. application Ser. No. 11/620,594, filed Jan. 5, 2007, now U.S. Pat. No. 9,357,977; which claims the benefit of Provisional Application 60/758,881, filed Jan. 12, 2006, the full disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4289132 | Rieman | Sep 1981 | A |
4802487 | Martin et al. | Feb 1989 | A |
4869258 | Hetz | Sep 1989 | A |
4936281 | Stasz | Jun 1990 | A |
5000185 | Yock | Mar 1991 | A |
5090414 | Takano | Feb 1992 | A |
5190050 | Nitzsche | Mar 1993 | A |
5315741 | Dubberke | May 1994 | A |
5335663 | Oakley et al. | Aug 1994 | A |
5372138 | Crowley et al. | Dec 1994 | A |
5372587 | Hammerslag et al. | Dec 1994 | A |
5456689 | Kresch et al. | Oct 1995 | A |
5469853 | Law et al. | Nov 1995 | A |
5471988 | Fujio et al. | Dec 1995 | A |
5474075 | Goldberg et al. | Dec 1995 | A |
5492126 | Hennige et al. | Feb 1996 | A |
5527331 | Kresch et al. | Jun 1996 | A |
5531676 | Edwards et al. | Jul 1996 | A |
5649911 | Trerotola | Jul 1997 | A |
5662664 | Gordon et al. | Sep 1997 | A |
5666954 | Chapelon et al. | Sep 1997 | A |
5697897 | Buchholtz et al. | Dec 1997 | A |
5730752 | Alden et al. | Mar 1998 | A |
5741287 | Alden et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5800378 | Edwards et al. | Sep 1998 | A |
5842994 | Tenhoff et al. | Dec 1998 | A |
5853368 | Solomon et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5863294 | Alden | Jan 1999 | A |
5873828 | Fujio et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5891137 | Chia et al. | Apr 1999 | A |
5906615 | Thompson | May 1999 | A |
5916198 | Dillow | Jun 1999 | A |
5957941 | Ream | Sep 1999 | A |
5964740 | Ouchi | Oct 1999 | A |
5979452 | Fogarty et al. | Nov 1999 | A |
5979453 | Savage | Nov 1999 | A |
5984942 | Alden et al. | Nov 1999 | A |
6002968 | Edwards | Dec 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6032673 | Savage et al. | Mar 2000 | A |
6039748 | Savage et al. | Mar 2000 | A |
6059766 | Greff | May 2000 | A |
6077257 | Edwards et al. | Jun 2000 | A |
6141577 | Rolland et al. | Oct 2000 | A |
6146378 | Mikus et al. | Nov 2000 | A |
6146380 | Racz et al. | Nov 2000 | A |
6158250 | Tibbals, Jr. et al. | Dec 2000 | A |
6171249 | Chin et al. | Jan 2001 | B1 |
6190383 | Schmaltz et al. | Feb 2001 | B1 |
6193714 | McGaffigan et al. | Feb 2001 | B1 |
6211153 | Garnick et al. | Apr 2001 | B1 |
6238336 | Ouchi | May 2001 | B1 |
6254601 | Burbank et al. | Jul 2001 | B1 |
6280441 | Ryan | Aug 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6306097 | Park et al. | Oct 2001 | B1 |
6306129 | Little et al. | Oct 2001 | B1 |
6315741 | Martin et al. | Nov 2001 | B1 |
6379348 | Onik | Apr 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6419048 | Robinson et al. | Jul 2002 | B1 |
6419648 | Vitek et al. | Jul 2002 | B1 |
6419653 | Edwards et al. | Jul 2002 | B2 |
6419673 | Edwards et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6432067 | Martin et al. | Aug 2002 | B1 |
6447477 | Burney et al. | Sep 2002 | B2 |
6461296 | Desai | Oct 2002 | B1 |
6463331 | Edwards | Oct 2002 | B1 |
6468228 | Topel et al. | Oct 2002 | B1 |
6475152 | Kelly, Jr. et al. | Nov 2002 | B1 |
6482203 | Paddock et al. | Nov 2002 | B2 |
6485413 | Boppart et al. | Nov 2002 | B1 |
6506154 | Ezion et al. | Jan 2003 | B1 |
6506156 | Jones et al. | Jan 2003 | B1 |
6506171 | Vitek et al. | Jan 2003 | B1 |
6507747 | Gowda et al. | Jan 2003 | B1 |
6508815 | Strul et al. | Jan 2003 | B1 |
6522142 | Freundlich | Feb 2003 | B1 |
6526320 | Mitchell | Feb 2003 | B2 |
6540677 | Angelsen et al. | Apr 2003 | B1 |
6543272 | Vitek | Apr 2003 | B1 |
6550482 | Burbank et al. | Apr 2003 | B1 |
6554780 | Sampson et al. | Apr 2003 | B1 |
6554801 | Steward et al. | Apr 2003 | B1 |
6559644 | Froundlich et al. | May 2003 | B2 |
6569159 | Edwards et al. | May 2003 | B1 |
6572613 | Ellman et al. | Jun 2003 | B1 |
6589237 | Woloszko et al. | Jul 2003 | B2 |
6592559 | Pakter et al. | Jul 2003 | B1 |
6602251 | Burbank et al. | Aug 2003 | B2 |
6610054 | Edwards et al. | Aug 2003 | B1 |
6612988 | Maor et al. | Sep 2003 | B2 |
6613004 | Vitek et al. | Sep 2003 | B1 |
6613005 | Friedman et al. | Sep 2003 | B1 |
6623481 | Garbagnati et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6632193 | Davison et al. | Oct 2003 | B1 |
6635055 | Cronin | Oct 2003 | B1 |
6635065 | Burbank et al. | Oct 2003 | B2 |
6638275 | McGaffigan et al. | Oct 2003 | B1 |
6638286 | Burbank et al. | Oct 2003 | B1 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6652516 | Gough | Nov 2003 | B1 |
6654202 | Rea et al. | Nov 2003 | B2 |
6660002 | Edwards et al. | Dec 2003 | B1 |
6660024 | Flaherty et al. | Dec 2003 | B1 |
6662680 | Rocket | Dec 2003 | B2 |
6663624 | Edwards et al. | Dec 2003 | B2 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6666833 | Friedman et al. | Dec 2003 | B1 |
6669643 | Dubinsky | Dec 2003 | B1 |
6679855 | Horn et al. | Jan 2004 | B2 |
6685639 | Wang et al. | Feb 2004 | B1 |
6689128 | Sliwa et al. | Feb 2004 | B2 |
6692490 | Edwards | Feb 2004 | B1 |
6701931 | Sliwa et al. | Mar 2004 | B2 |
6705994 | Vortman et al. | Mar 2004 | B2 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6716184 | Vaezy et al. | Apr 2004 | B2 |
6719755 | Sliwa et al. | Apr 2004 | B2 |
6728571 | Barbato | Apr 2004 | B1 |
6730081 | Desai | May 2004 | B1 |
6735461 | Vitek et al. | May 2004 | B2 |
6743184 | Sampson et al. | Jun 2004 | B2 |
6746447 | Davison et al. | Jun 2004 | B2 |
6764488 | Burbank et al. | Jul 2004 | B1 |
6773431 | Eggers et al. | Aug 2004 | B2 |
6790180 | Vitek | Sep 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6805129 | Pless et al. | Oct 2004 | B1 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6832996 | Woloszko et al. | Dec 2004 | B2 |
6837887 | Woloszko et al. | Jan 2005 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6840935 | Lee | Jan 2005 | B2 |
6936048 | Hurst | Aug 2005 | B2 |
6938048 | Jilk et al. | Aug 2005 | B1 |
6944490 | Chow | Sep 2005 | B1 |
6969354 | Marian | Nov 2005 | B1 |
6994706 | Chornenky et al. | Feb 2006 | B2 |
7160296 | Pearson et al. | Jan 2007 | B2 |
7229401 | Kindlein | Jun 2007 | B2 |
7247141 | Makin et al. | Jul 2007 | B2 |
7331957 | Woloszko et al. | Feb 2008 | B2 |
7387628 | Behl et al. | Jun 2008 | B1 |
7517346 | Sloan et al. | Apr 2009 | B2 |
7549424 | Desai | Jun 2009 | B2 |
7771357 | Burbank et al. | Aug 2010 | B2 |
7815571 | Gerbi et al. | Oct 2010 | B2 |
7874986 | Deckman et al. | Jan 2011 | B2 |
7918795 | Grossman | Apr 2011 | B2 |
7963941 | Wilk | Jun 2011 | B2 |
8080009 | Lee et al. | Dec 2011 | B2 |
8088072 | Munrow et al. | Jan 2012 | B2 |
8157741 | Hirota | Apr 2012 | B2 |
8157745 | Schoot | Apr 2012 | B2 |
8216231 | Behl et al. | Jul 2012 | B2 |
8221321 | McMorrow et al. | Jul 2012 | B2 |
8287485 | Kimura et al. | Oct 2012 | B2 |
8377041 | Frassica et al. | Feb 2013 | B2 |
8469893 | Chiang et al. | Jun 2013 | B2 |
8506485 | Deckman et al. | Aug 2013 | B2 |
8512330 | Epstein et al. | Aug 2013 | B2 |
8512333 | Epstein et al. | Aug 2013 | B2 |
8540634 | Bruce et al. | Sep 2013 | B2 |
8585598 | Razzaque et al. | Nov 2013 | B2 |
8622911 | Hossack et al. | Jan 2014 | B2 |
8663130 | Neubach et al. | Mar 2014 | B2 |
8718339 | Tonomura et al. | May 2014 | B2 |
8814796 | Martin et al. | Aug 2014 | B2 |
8992427 | Munrow et al. | Mar 2015 | B2 |
9089287 | Sliwa et al. | Jul 2015 | B2 |
9198707 | McKay et al. | Dec 2015 | B2 |
9198719 | Murdeshwar et al. | Dec 2015 | B2 |
9247925 | Havel et al. | Feb 2016 | B2 |
9357977 | Grossman | Jun 2016 | B2 |
9439627 | Case et al. | Sep 2016 | B2 |
9510898 | Epstein et al. | Dec 2016 | B2 |
9516996 | Diolaiti et al. | Dec 2016 | B2 |
9517047 | Grossman | Dec 2016 | B2 |
9987080 | Grossman | Jun 2018 | B2 |
10182862 | Grossman | Jan 2019 | B2 |
20010014805 | Burbank | Aug 2001 | A1 |
20010051802 | Woloszko et al. | Dec 2001 | A1 |
20020002393 | Mitchell | Jan 2002 | A1 |
20020022835 | Lee | Feb 2002 | A1 |
20020052600 | Davison et al. | May 2002 | A1 |
20020068871 | Mendlein et al. | Jun 2002 | A1 |
20020077550 | Rabiner et al. | Jun 2002 | A1 |
20020156373 | Wakabayashi et al. | Oct 2002 | A1 |
20020183735 | Edwards et al. | Dec 2002 | A1 |
20030009164 | Woloszko et al. | Jan 2003 | A1 |
20030014046 | Edwards et al. | Jan 2003 | A1 |
20030028111 | Vaezy et al. | Feb 2003 | A1 |
20030032896 | Bosley et al. | Feb 2003 | A1 |
20030045768 | Hirooka | Mar 2003 | A1 |
20030114732 | Webler et al. | Jun 2003 | A1 |
20030130575 | Desai | Jul 2003 | A1 |
20030130655 | Woloszko et al. | Jul 2003 | A1 |
20030130665 | Pinczewski et al. | Jul 2003 | A1 |
20030195420 | Mendlein et al. | Oct 2003 | A1 |
20030195496 | Maguire et al. | Oct 2003 | A1 |
20030199472 | Al-Hendy et al. | Oct 2003 | A1 |
20030216725 | Woloszko et al. | Nov 2003 | A1 |
20030216759 | Burbank et al. | Nov 2003 | A1 |
20040002699 | Ryan et al. | Jan 2004 | A1 |
20040006336 | Swanson | Jan 2004 | A1 |
20040030268 | Weng et al. | Feb 2004 | A1 |
20040054366 | Davison et al. | Mar 2004 | A1 |
20040082883 | Kohno | Apr 2004 | A1 |
20040120668 | Loeb | Jun 2004 | A1 |
20040143252 | Hurst | Jul 2004 | A1 |
20040153057 | Davison | Aug 2004 | A1 |
20040175399 | Schiffman | Sep 2004 | A1 |
20040176760 | Qiu | Sep 2004 | A1 |
20040193028 | Jones et al. | Sep 2004 | A1 |
20040193238 | Mosher | Sep 2004 | A1 |
20040199179 | Elliott | Oct 2004 | A1 |
20040215182 | Lee | Oct 2004 | A1 |
20040230190 | Dahla et al. | Nov 2004 | A1 |
20040254572 | McIntyre et al. | Dec 2004 | A1 |
20050038340 | Vaezy et al. | Feb 2005 | A1 |
20050085730 | Flesch et al. | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050107781 | Ostrovsky et al. | May 2005 | A1 |
20050124882 | Ladabaum et al. | Jun 2005 | A1 |
20050149013 | Lee | Jul 2005 | A1 |
20050177209 | Leung et al. | Aug 2005 | A1 |
20050197577 | Makin et al. | Sep 2005 | A1 |
20050203410 | Jenkins | Sep 2005 | A1 |
20050215990 | Govari | Sep 2005 | A1 |
20050216039 | Lederman | Sep 2005 | A1 |
20050228288 | Hurst | Oct 2005 | A1 |
20050255039 | Desai | Nov 2005 | A1 |
20050256405 | Makin et al. | Nov 2005 | A1 |
20060010207 | Akerman et al. | Jan 2006 | A1 |
20060018665 | Shibata et al. | Jan 2006 | A1 |
20060058680 | Solomon | Mar 2006 | A1 |
20060178665 | Sloan et al. | Aug 2006 | A1 |
20060184049 | Tsujita | Aug 2006 | A1 |
20060189972 | Grossman | Aug 2006 | A1 |
20060241368 | Fichtinger et al. | Oct 2006 | A1 |
20070006215 | Epstein et al. | Jan 2007 | A1 |
20070161905 | Munrow | Jul 2007 | A1 |
20070249936 | Deckman et al. | Oct 2007 | A1 |
20070249939 | Gerbi et al. | Oct 2007 | A1 |
20080033493 | Deckman et al. | Feb 2008 | A1 |
20080228081 | Becker et al. | Sep 2008 | A1 |
20090043295 | Arnal et al. | Feb 2009 | A1 |
20090131790 | Munrow et al. | May 2009 | A1 |
20090287081 | Grossman et al. | Nov 2009 | A1 |
20100056926 | Deckman et al. | Mar 2010 | A1 |
20100262133 | Hoey et al. | Oct 2010 | A1 |
20110087100 | Grossman | Apr 2011 | A1 |
20110288412 | Deckman et al. | Nov 2011 | A1 |
20120035474 | Deckman et al. | Feb 2012 | A1 |
20120071794 | Karni | Mar 2012 | A1 |
20120078134 | Munrow et al. | Mar 2012 | A1 |
20120165813 | Lee et al. | Jun 2012 | A1 |
20120209115 | Tonomura | Aug 2012 | A1 |
20120277737 | Curley | Nov 2012 | A1 |
20120316440 | Munrow et al. | Dec 2012 | A1 |
20130281863 | Chiang et al. | Oct 2013 | A1 |
20130296699 | Deckman et al. | Nov 2013 | A1 |
20130317366 | Hirayama et al. | Nov 2013 | A1 |
20140180273 | Nair | Jun 2014 | A1 |
20140276081 | Tegels | Sep 2014 | A1 |
20150150497 | Goldchmit | Jun 2015 | A1 |
20150173592 | Leeflang et al. | Jun 2015 | A1 |
20150257779 | Sinelnikov et al. | Sep 2015 | A1 |
20160151041 | Lee et al. | Jun 2016 | A1 |
20160278740 | Negrila et al. | Sep 2016 | A1 |
20160310042 | Kesten et al. | Oct 2016 | A1 |
20180078303 | Grossman | Mar 2018 | A1 |
20190192217 | Grossman | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
WO-9528129 | Oct 1995 | WO |
WO-9717105 | May 1997 | WO |
WO-9811834 | Mar 1998 | WO |
WO-9814169 | Apr 1998 | WO |
WO-9943366 | Sep 1999 | WO |
WO-0000098 | Jan 2000 | WO |
WO-0180723 | Nov 2001 | WO |
WO-0195819 | Dec 2001 | WO |
WO-0211639 | Feb 2002 | WO |
WO-0180723 | Apr 2002 | WO |
WO-03005882 | Jan 2003 | WO |
WO-03065908 | Aug 2003 | WO |
WO-03088833 | Oct 2003 | WO |
WO-03005882 | Nov 2003 | WO |
WO-2004002293 | Jan 2004 | WO |
WO-2004002550 | Jan 2004 | WO |
WO-2004020011 | Mar 2004 | WO |
WO-2004035110 | Apr 2004 | WO |
WO-2004035110 | Jun 2004 | WO |
WO-2004058328 | Jul 2004 | WO |
WO-2004064658 | Aug 2004 | WO |
WO-2004002550 | Oct 2004 | WO |
WO-2004058328 | Oct 2004 | WO |
WO-2004002293 | Jul 2005 | WO |
WO-2007124265 | Nov 2007 | WO |
WO-2007149595 | Dec 2007 | WO |
WO-2014039795 | Mar 2014 | WO |
Entry |
---|
Alterovitz, et al. Simulating Needle Insertion and Radioactive Seed Implantation for Prostate Brachytherapy. Medicine Meets Virtual Reality 11, Westwood et al. (Eds.), IOS Press, Jan. 2003, pp. 19-25. |
Bergamini, et al. Laparoscopic Radiofrequency Thermal Ablation: A New Approach to Symptomatic Uterine Myomas. Am. J. Obstetrics and Gynecology (2005) 192: 768-73. |
CNN.com Health Women. Experimental technique uses lasers to shrink uterine fibroids. Nov. 28, 2000. |
Co-pending U.S. Appl. No. 15/634,368, filed Jun. 27, 2017. |
European Office Action dated Apr. 21, 2016 for EP07760319.9. |
Extended European search report and search opinion dated Nov. 23, 2010 for EP 07760319.9. |
Hindley, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: Early results. American Journal of Roentgenology, 2004, 183(6): 1173-1719. |
International search report and written opinion dated Nov. 13, 2007 for PCT/US2007/066235. |
Kanaoka, et al. Microwave endometrial ablation at a frequency of 2.45 Ghz. A pilot study. J Reprod Med. Jun. 2001; 46(60): 559-63. |
Law, et al. Magnetic resonance-guided percutaneous laser ablation of uterine fibroids. J Magn Reson Imaging, Oct. 2000; 12(4):565-70. |
Liu, et al. Catheter-Based Intraluminal Sonography. J. Ultrasound Med., 2004, 23:145-160. |
Mogami, et al. Usefulness of MR-guided percutaneous cryotherapy. Med. Imaging Technol. 2004, 22(3): 131-6. (English abstract). |
MSNBC Online Articles, About US: Articles; “Intrauerine Fibroids Can Now Be Treated Nonsurgically” http://www.fibroids.com/news-blog/2004/08/intrauterine-fibroids-can-now-be-treated-nonsurgically/ Aug. 23, 2004. |
Notice of allowance dated May 8, 2013 for U.S. Appl. No. 12/973,587. |
Notice of allowance dated Jul. 22, 2010 for U.S. Appl. No. 11/409,496. |
Notice of allowance dated Sep. 16, 2010 for U.S. Appl. No. 11/564,164. |
Office action dated Jan. 7, 2009 for U.S. Appl. No. 11/564,164. |
Office action dated Feb. 26, 2013 for U.S. Appl. No. 12/973,587. |
Office action dated Mar. 3, 2010 for U.S. Appl. No. 11/564,164. |
Office action dated Jun. 13, 2012 for U.S. Appl. No. 12/973,587. |
Office action dated Jun. 18, 2015 for U.S. Appl. No. 13/667,891. |
Office action dated Jul. 19, 2010 for U.S. Appl. No. 11/564,164. |
Office action dated Jul. 22, 2009 for U.S. Appl. No. 11/409,496. |
Office action dated Sep. 23, 2009 for U.S. Appl. No. 11/564,164. |
Office action dated Sep. 24, 2012 for U.S. Appl. No. 12/973,587. |
Office action dated Nov. 3, 2014 for U.S. Appl. No. 13/667,891. |
Office action dated Dec. 23, 2009 for U.S. Appl. No. 11/409,496. |
Office action dated Dec. 24, 2008 for U.S. Appl. No. 11/409,496. |
Okamura, et al. Force Modeling for Needle Insertion into Soft Tissue. IEEE Transactions on Biomedical Engineering, Oct. 2001, 10 (51): 1707-1716. |
RSNA 2000 Explore News Release. Lasers Liquefy Uterine Fibroid Tumors. 11:30 a.m. CST, Monday, Nov. 27, 2000. |
Senoh, et al. Saline Infusion Contrast Intrauterine Sonographic Assessment of the Endometrium with High-Frequency, Real-Time Miniature Transducer Normal Menstrual Cycle: a Preliminary Report. Human Reproduction, 14 (10): 2600-2603, 1999. |
Vascular and Interventional Radiology, SRSC; Nonsurgical Treatment of Uterine Fibroids. Available at http://www.drfibroid.com/treatment.htm. Accessed Apr. 11, 2011. |
WebSand, Inc., New treatment options for fibroid tumors, Copyright 2002 by WebSand, Inc. |
International Search Report and Written Opinion dated Jan. 17, 2018 for International PCT Patent Application No. PCT/US2017/061366. |
International search report and written opinion dated Mar. 3, 2008 for PCT/US2007/060306. |
Notice of allowance dated Feb. 25, 2016 for U.S. Appl. No. 11/620,594. |
Notice of Allowance dated Mar. 13, 2018 for U.S. Appl. No. 15/720,199. |
Notice of Allowance dated Jul. 19, 2017 for U.S. Appl. No. 12/973,642. |
Notice of Allowance dated Aug. 10, 2017 for U.S. Appl. No. 12/973,642. |
Notice of Allowance dated Sep. 21, 2016 for U.S. Appl. No. 15/150,813. |
Notice of allowance dated Oct. 5, 2010 for U.S. Appl. No. 11/347,018. |
Notice of Allowance dated Oct. 21, 2016 for U.S. Appl. No. 15/150,813. |
Office action dated Jan. 21, 2015 for U.S. Appl. No. 12/973,642. |
Office action dated Jan. 23, 2009 for U.S. Appl. No. 11/347,018. |
Office action dated Feb. 25, 2013 for U.S. Appl. No. 12/973,642. |
Office action dated Mar. 20, 2014 for U.S. Appl. No. 12/973,642. |
Office action dated Apr. 2, 2010 for U.S. Appl. No. 11/620,594. |
Office action dated Apr. 6, 2016 for U.S. Appl. No. 12/973,642. |
Office action dated May 25, 2012 for U.S. Appl. No. 12/973,642. |
Office action dated Jun. 18, 2012 for U.S. Appl. No. 11/620,594. |
Office action dated Aug. 28, 2012 for U.S. Appl. No. 11/620,594. |
Office action dated Sep. 17, 2009 for U.S. Appl. No. 11/347,018. |
Office Action dated Oct. 21, 2016 for U.S. Appl. No. 12/973,642. |
Office action dated Oct. 22, 2015 for U.S. Appl. No. 12/973,642. |
Office action dated Nov. 3, 2010 for U.S. Appl. No. 11/620,594. |
Office action dated Nov. 6, 2013 for U.S. Appl. No. 12/973,642. |
Office Action dated Nov. 17, 2017 for U.S. Appl. No. 15/720,199. |
Office action dated Dec. 22, 2009 for U.S. Appl. No. 11/347,018. |
Supplementary European search report and search opinion dated Oct. 29, 2009 for EP 07797073.9. |
U.S. Appl. No. 13/667,891 Notice of Allowance dated Mar. 1, 2018. |
Office action dated Jun. 2, 2020 for U.S. Appl. No. 15/634,368. |
Office action dated Jul. 27, 2020 for U.S. Appl. No. 15/824,511. |
Number | Date | Country | |
---|---|---|---|
20170290626 A1 | Oct 2017 | US |
Number | Date | Country | |
---|---|---|---|
60758881 | Jan 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13667891 | Nov 2012 | US |
Child | 15628166 | US | |
Parent | 11564164 | Nov 2006 | US |
Child | 12973587 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12973587 | Dec 2010 | US |
Child | 13667891 | US | |
Parent | 11409496 | Apr 2006 | US |
Child | 11564164 | US | |
Parent | 11620591 | Jan 2007 | US |
Child | 13667891 | Nov 2012 | US |